Dr. Lal PathLabs Limited (LALPATHLAB) AI Stock Analysis

• Market Cap: ₹284.20B
• Dividend Yield: 0.73%
• Average Volume (3M): 5.17K
• Price to Earnings (P/E): 55.1
• Beta (1Y): 0.49
• Revenue Growth: 10.57%
• EPS Growth: 34.11%
• Country: IN
• Employees: 4,099
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 15.87
• Shares Outstanding: 83,775,510
• 10 Day Avg. Volume: 6,546
• 30 Day Avg. Volume: 5,171
• PEG Ratio: 1.15
• Price to Book (P/B): 9.21
• Price to Sales (P/S): 8.13
• P/FCF Ratio: 38.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹3,454.33
• Price Target Upside: 4.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 70 Outperform
• Price Target: ₹3,493.00 ▲(5.73% Upside)

Dr. Lal PathLabs scores a 70, driven by strong financial performance and bullish technical indicators. However, the high valuation reflects potential overpricing, and the absence of significant earnings call insights or corporate events limits further analysis. Investors should weigh the robust financial health and growth potential against the current market valuation.

Dr. Lal PathLabs Limited Business Overview & Revenue Model

Company Description

Dr. Lal PathLabs Limited (LALPATHLAB) is a leading diagnostic and healthcare service provider in India, renowned for offering a wide range of diagnostic and related healthcare services. Established with a focus on quality and reliability, the company operates a network of laboratories, patient service centers, and pick-up points across the country. Its core services include routine and specialized testing services in areas such as biochemistry, hematology, clinical pathology, microbiology, and molecular diagnostics, catering to the needs of patients, physicians, and hospitals.

How the Company Makes Money

Dr. Lal PathLabs Limited generates revenue primarily through the provision of diagnostic and testing services. The company's revenue model is centered around conducting a variety of tests, ranging from routine blood tests to complex genetic and molecular diagnostics. Key revenue streams include fees charged for tests and diagnostics conducted at their laboratories and service centers. The company also collaborates with hospitals and clinics to offer specialized pathology services. Additional revenue is derived from home collection services, where samples are collected from patients' homes, providing convenience and accessibility. Dr. Lal PathLabs has also engaged in strategic partnerships and alliances to enhance its service offerings and expand its reach, contributing to its revenue growth.

Dr. Lal PathLabs Limited Financial Statement Overview

Summary

Dr. Lal PathLabs exhibits a robust financial position characterized by significant revenue and profit growth, efficient operational margins, and a stable balance sheet. Strong cash-generating capabilities further enhance its financial health, positioning the company for future growth despite some areas for improvement in return metrics.

Income Statement

Dr. Lal PathLabs showed strong financial performance with a consistent increase in total revenue over the years, marking a significant growth rate from 2024 to 2025. The company enjoys robust profit margins with a gross profit margin of approximately 60.8% and a net profit margin of about 19.8% in the latest year. Both EBIT and EBITDA margins indicate healthy operational efficiency, demonstrating the company's ability to convert revenue into profits effectively.

Balance Sheet

The company maintains a solid financial structure with a low debt-to-equity ratio, indicating conservative leverage. The equity ratio is strong, suggesting a high level of equity financing relative to assets. However, the return on equity shows room for improvement, reflecting moderate efficiency in generating returns for shareholders. The overall balance sheet displays stability and low-risk financial management.

Cash Flow

The cash flow statement reveals a positive trajectory in operating cash flow, aligning well with net income and showcasing strong cash-generating capabilities. Free cash flow has grown significantly, highlighting efficient capital expenditure management and prudent cash utilization. Despite some fluctuations in investing and financing cash flows, the company demonstrates an ability to maintain liquidity and support its growth strategies.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	24.61B	24.61B	22.27B	20.17B	20.87B	15.81B
Gross Profit	12.90B	14.97B	12.79B	15.70B	13.00B	11.84B
EBITDA	7.62B	6.96B	6.78B	5.32B	6.13B	4.88B
Net Income	4.87B	4.87B	3.58B	2.39B	3.45B	2.92B
Balance Sheet
Total Assets	27.17B	27.17B	24.56B	23.86B	23.53B	16.61B
Cash, Cash Equivalents and Short-Term Investments	11.65B	11.65B	9.43B	8.51B	6.82B	9.84B
Total Debt	1.57B	1.57B	2.47B	4.20B	5.32B	1.50B
Total Liabilities	5.10B	5.10B	5.71B	6.86B	8.10B	3.85B
Stockholders Equity	21.73B	21.73B	18.49B	16.66B	15.08B	12.45B
Cash Flow
Free Cash Flow	0.00	5.25B	4.78B	4.11B	-294.49M	3.39B
Operating Cash Flow	0.00	5.69B	5.35B	4.56B	4.47B	3.98B
Investing Cash Flow	0.00	-3.03B	-242.69M	-2.87B	-4.49B	-2.12B
Financing Cash Flow	0.00	-3.34B	-4.14B	-2.83B	1.36B	-1.39B

Dr. Lal PathLabs Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3303.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Positive. The current price of 3303.55 is above the 20-day moving average (MA) of 3293.68, above the 50-day MA of 3221.06, and above the 200-day MA of 2879.78, indicating a bullish trend. The MACD of 31.75 indicates Positive momentum. The RSI at 51.43 is Neutral, neither overbought nor oversold. The STOCH value of 39.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LALPATHLAB.

Dr. Lal PathLabs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LALPATHLAB	70 Outperform	₹284.20B	55.09	―	0.73%	10.57%	34.11%
THYROCARE	69 Neutral	63.88B	59.85	16.74%	1.74%	21.82%	36.97%
METROPOLIS	68 Neutral	107.74B	70.44	10.89%	―	12.86%	10.42%
VIJAYA	68 Neutral	108.14B	71.71	17.98%	0.19%	22.34%	20.71%
KRSNAA	63 Neutral	27.44B	34.90	8.79%	0.32%	13.78%	32.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%